Off-axis beam optimization reduced lung dose in posterior lung stereotactic body radiotherapy
Off-axis beam optimization preserved target coverage while reducing lung dose and enabling collision-free beam geometry for posterior lung lesions.
Off-axis beam optimization preserved target coverage while reducing lung dose and enabling collision-free beam geometry for posterior lung lesions.
Oxygen-ion irradiation showed higher biological effectiveness and more persistent DNA damage than carbon ions or photons in pancreatic cancer cells.
Splitting eight fractions between inhale and exhale breath-holds reduced maximum rib dose from 67.9 to 33.5 Gy without compromising target coverage.
Robust optimization preserved target coverage while reducing lung, heart, esophageal, spinal cord, and estimated immune-cell dose during long-course lung radiotherapy.
Multimodal registration, motion management, and arrhythmia substrate definition were the highest-risk steps in stereotactic arrhythmia radioablation.
A 40 Gy equivalent dose to at least 18% of the left anterior descending artery was associated with more than twofold risk of cardiac events.
The neural model reduced phase-space storage from 3 gigabytes to 600 kilobytes while maintaining at least 89.9% gamma passing at 1%/1 mm.
Definitive intensity-modulated radiotherapy alone achieved 93.0% three-year overall survival, with no recurrence solely within omitted prophylactic nodal regions.
The framework achieved 85.5% external-validation accuracy and reduced estimated review time from 822 hours to 2.3–4.8 hours.
Weekly cisplatin remained non-inferior to three-weekly cisplatin at five years in postoperative high-risk head and neck chemoradiotherapy.
Absorbed dose near the applicator varied markedly by tissue composition despite accurate Monte Carlo calculation by the treatment planning system.
Tumour volume reduction above 40% during radiotherapy was independently associated with improved overall survival in patients with oropharyngeal cancer.
Preoperative radiotherapy was not associated with greater renal dysfunction after nephrectomy for retroperitoneal sarcoma during follow-up extending to 80 months.
ESTRO–ASTRO guidance supports selected rectal cancer reirradiation using 30–40 Gy regimens, cumulative dose assessment, inverse planning and daily volumetric imaging.
Regional diffusion changes distinguished patients who developed contrast-enhancing brain lesions as early as six months after proton therapy.